


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.07%
-2.01%
-3.10%
0.00%
LEGN
Legend Biotech Corporatio
$19.01
Strengths

Outperform the market

Upgraded on attractively valued
LEGN Price Performance
$22.53 (-15.62%)
$32.13 (-40.83%)
$34.22 (-44.45%)
$35.73 (-46.80%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
LEGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
LEGN Street Sentiment is bullish and have positive views on the near-term outlook
LEGN has Low risk level

Average key support and resistance price levels
What is LEGN current stock price?
What are LEGN stock strengths?
What is LEGN Risk Level?
What is LEGN market cap and volume?
What is LEGN current Stock IQ?
Should I buy LEGN stock right now?
Is LEGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for LEGN?
What does a 'Strong Sell' rating mean for LEGN?
What factors influence LEGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.07%
-2.01%
-3.10%
0.00%
LEGN
Legend Biotech Corporatio
Current Price
$19.01
Stock Insights
Strengths

Outperform the market

Upgraded on attractively valued

LEGN Price Performance
$22.53 (-15.62%)
$32.13 (-40.83%)
$34.22 (-44.45%)
$35.73 (-46.80%)
LEGN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
LEGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
LEGN Street Sentiment is bullish and have positive views on the near-term outlook
LEGN has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 08, 2026
Initiate
Outperform
Oppenheimer
Dec 18, 2025
Reiterate
Overweight
Cantor Fitzgerald
Dec 13, 2025
Reiterate
Overweight
Morgan Stanley
Dec 09, 2025
Reiterate
Buy
UBS
Nov 14, 2025
Reiterate
Outperform
RBC
Nov 14, 2025
Reiterate
Overweight
Cantor Fitzgerald
Nov 14, 2025
Reiterate
Overweight
Barclays
LEGN Stock IQ
LEGN Latest Analysis
Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds.
Fri Jan 23, 2026
Raymond James reiterates Outperform rating on Legend Biotech stock.
Tue Jan 20, 2026
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints.
Tue Jan 20, 2026
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Wed Jan 14, 2026
Cantor Fitzgerald and RBC Capital Stay ish on Legend Biotech (LEGN). Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 17 Cantor Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition even though [….]
Fri Jan 9, 2026
Oppenheimer Initiates Coverage of Legend Biotech Corporation - Depositary Receipt (LEGN) with Outperform Recommendation. Fintel reports that on January 7 2026 Oppenheimer initiated coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS:LEGN) with a Outperform recommendation. Analyst Price Forecast Suggests 242.25% Upside
Thu Jan 8, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LEGN Stock trends
LEGN Stock performance
LEGN Stock analysis
LEGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.